Embecta Corp. focuses on diabetes products and recently received FDA approval for a new patch pump. Read why I'm neutral on ...

The Federal Trade Commission said pharmacy benefit managers created a "perverse drug rebate system" that artificially ...

Millions of Americans with diabetes need insulin to survive, yet for many of these vulnerable patients, their insulin drug ...

The Federal Trade Commission (FTC) has filed a legal complaint accusing the 3 largest pharmacy benefit managers (PBMs) in the ...

The three price benefit managers jointly administer 80% of all prescriptions in the U.S., the FTC said in the lawsuit.

MADRID — Day of the week, age, snacking, and being more engaged with smart insulin pens are important factors that affect ...

The move to self-administration with a syringe and needle, just like how insulin is often taken for diabetes, means a whole ...

The global rapid-acting insulin market is expected to grow at a CAGR of 4.75% and reach US$ 11.17 billion by 2032, from US$ 7.36 billion in 2023. The market is mainly driven by growth rate of diabetes ...

The global insulin pens market is experiencing rapid expansion, driven by the rising global prevalence of diabetes. According ...

Key drivers include technological advancements and evolving healthcare policies. The global market for short-acting insulin ...

Weight loss is beneficial for reducing blood sugars because it improves insulin sensitivity. According to the ADA, modest, persistent weight loss can delay the progression from prediabetes to type 2 ...

The World Health Organization issued a warning last year about insulin pens relabeled and repackaged to look like Ozempic.